Evommune, Inc. (EVMN)
| Market Cap | 581.10M |
| Revenue (ttm) | 3.00M |
| Net Income (ttm) | -66.26M |
| Shares Out | 30.08M |
| EPS (ttm) | -5.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66 |
| Open | 19.10 |
| Previous Close | 19.32 |
| Day's Range | 18.85 - 19.22 |
| 52-Week Range | 16.70 - 24.03 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About EVMN
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California. [Read more]
News
Evommune Announces Pricing of its Initial Public Offering
PALO ALTO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory dis...
Evommune Announces Commencement of Initial Public Offering
PALO ALTO, Calif. , Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory di...
Evommune Aims For IPO In Bifurcated Biopharma Market
Evommune, Inc. is seeking to raise $100 million in an IPO to advance its pipeline of inflammatory disease treatments. EVMN's lead candidate, EVO756, is in Phase 2 trials for chronic spontaneous urtica...
Evommune files for IPO to advance immune drug work
The company has a pair of drugs in mid-stage testing for urticarias and atopic dermatitis.
Evommune IPO Registration Document (S-1)
Evommune has filed to go public with an IPO on the New York Stock Exchange (NYSE)
Chronic inflammatory disease biotech Evommune files for a $100 million IPO
Evommune, a Phase 2 biotech developing therapies for chronic inflammatory diseases, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.